RELISTOR's Effects on Opioid-Induced Constipation

NCT ID: NCT04930237

Last Updated: 2022-05-03

Basic Information

• Recruitment Status: WITHDRAWN
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-07-01
• Study Completion Date: 2022-04-22

Brief Summary

This will be a prospective case-control study of 40 patients undergoing 1-2 level ALIF procedures at Methodist Dallas Medical Center (MDMC). Patient records will be reviewed to identify details including demographics, comorbidities, procedure details, and the primary and secondary outcome metrics.

Detailed Description

RELISTOR is a legally marketed device and will be used off-label under the authority of a health care practitioner within a legitimate practitioner-patient relationship with the intent of the "practice of medicine".

The use of RELISTOR in the experimental group of this study meets all of the following conditions:

• is not intended to be reported to the FDA in support of a new indication for use or to support any other significant change in the labeling for the drug;
• it is not intended to support a significant change in the advertising for the product;
• it does not involve a route of administration or dosage level, use in a subject population, or other factor that significantly increases the risks (or decreases the acceptability of the risks) associated with the use of the drug product;
• it is conducted in compliance with the requirements for IRB review and informed consent [21 CFR parts 56 and 50, respectively];
• it is conducted in compliance with the requirements concerning the promotion and sale of drugs [21 CFR 312.7]; and
• it does not intend to invoke 21 CFR 50.24

Screening and Enrollment:

Patients will undergo two levels of screening: the initial screening and a post-operative OIC screening. The initial screening will involve all 1-2 level ALIF patients in the experimental group and observational group who will be approached to participate in the study before surgery. After eligible patients agree to participate and sign the ICF, all patients will then be asked to complete the PAC-SYM instrument about their constipation symptoms over the past 2 weeks.

Patients in both groups will undergo their 1-2 level ALIF procedure and then will undergo the post-operative OIC screen/rescreen (as needed) daily for acute OIC for a maximum of 3 days (i.e., postoperative days 2 - 4). Patients who are found to have acute OIC will be designated to the experimental and observational treatment regimens accordingly to Study Treatment Regimens.

If a patient does not have acute OIC after they are rescreened on postoperative day 4, are discharged, or do not meet the inclusion criteria, will be placed in the not-constipated or post-operative screen failure group.

Conditions

OIC

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

Experimental Group

Patients who receive RELISTOR

Relistor Injectable Product

Intervention Type: DRUG

12-mg RELISTOR to be administered as once-daily subcutaneous injections for 4 to 7 days

Observational Group

Patients that receive standard of care

Docusate Calcium

Intervention Type: DRUG

Standard of care

Bisacodyl

Intervention Type: DRUG

Standard of Care

Milk of magnesia

Intervention Type: DRUG

Standard of Care

Magnesium citrate

Intervention Type: DRUG

Standard of Care

Senna

Intervention Type: DRUG

Standard of Care

Enema

Intervention Type: DRUG

Standard of Care

Interventions

Relistor Injectable Product

12-mg RELISTOR to be administered as once-daily subcutaneous injections for 4 to 7 days

Intervention Type: DRUG

Docusate Calcium

Standard of care

Intervention Type: DRUG

Bisacodyl

Standard of Care

Intervention Type: DRUG

Milk of magnesia

Standard of Care

Intervention Type: DRUG

Magnesium citrate

Standard of Care

Intervention Type: DRUG

Senna

Standard of Care

Intervention Type: DRUG

Enema

Standard of Care

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Experimental Group (initial screen):

• Age 18 years or older
• Inpatient who will undergo a 1-2 level ALIF procedure with Dr. Richard Meyrat
• Are not pregnant or lactating
• Does not have a history of drug abuse within the past 2 years
• Does not have a gastrointestinal ostomy

Experimental Group (post-operative OIC screen/rescreen)

• Actively constipated (i.e., no BM in last 48 hours, difficult having a spontaneous BM, or inability to have a spontaneous BM)
• Receiving mu-agonist opioids
• Expected to require daily opioid analgesics for at least 7 days following enrollment
• Have not received or discontinued use of any laxatives, enemas and/or promotility agents within 48 hours of enrollment and the first dose of RELISTOR. Stool softeners are permitted.
• Does not have a known hypersensitivity to methylnaltrexone, naltrexone, or naloxone

Observational Group (initial screen):

• Age 18 years or older
• Inpatient who will undergo 1-2 level ALIF procedure with Dr. Graham
• Are not pregnant or lactating
• Does not have a history of drug abuse within the past 2 years
• Does not have a gastrointestinal ostomy

Observational Group (post-operative OIC screen/rescreen):

• Actively constipated (i.e. no BM in last 48 hours, difficulty having a spontaneous BM, or inability to have a spontaneous BM)
• Receiving mu-agonist opioids
• Expected to require daily opioid analgesics for at least 7 days following enrollment

Exclusion Criteria

Experimental Group (post-operative OIC screen/rescreen):

Exclude patients with:

• Fecal impaction
• Mechanical bowel obstruction
• Constipation not attributed to post-procedural opioid use
• Calculated creatinine clearance less than 50 mL/min
• Corrected QT interval greater than 500 msec. on a 12-lead screening electrocardiogram

Observational Group (post-operative OIC screen/rescreen):

Exclude patients with:

• Fecal impaction
• Mechanical bowel obstruction
• Constipation not attributed to post-procedural opioid use

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Methodist Health System

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Richard Meyrat, MD

Role: PRINCIPAL_INVESTIGATOR

The Methodist Hospital Research Institute

Locations

Methodist Moody Brain and Spine Institute, Methodist Dallas Medical Center

Dallas, Texas, United States

Countries

United States

Other Identifiers

013.MBSI.2021.D

Identifier Type: -

Identifier Source: org_study_id